Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Athens Medical CentreFRA:ACS +2.11%63 EV-to-EBITDA is 10.58 as of Aug. 03, 2026, which is 11% above its 10-year median of 9.55. GuruFocus rates FRA:ACS with a GF Score™ of 63/100 and a GF Value™ of €1.78. The stock has 9 warning signs investors should review. Among 509 Healthcare Providers & Services companies, Athens Medical Centre ranks better than 52.65% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Athens Medical Centre's enterprise value is €294.1 Mil.
Athens Medical Centre's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €27.8 Mil. Therefore, Athens Medical Centre's EV-to-EBITDA for today is 10.58.
The historical rank and industry rank for Athens Medical Centre's EV-to-EBITDA or its related term are showing as below:
FRA:ACS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.15 Med: 9.55 Max: 211.64
Current: 10.57
During the past 13 years, the highest EV-to-EBITDA of Athens Medical Centre was 211.64. The lowest was 6.15. And the median was 9.55.
FRA:ACS's EV-to-EBITDA is ranked better than 52.65% of 509
companies
in the Healthcare Providers & Services industry
Industry Median: 11.07
vs FRA:ACS: 10.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Athens Medical Centre (FRA:ACS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Athens Medical Centre's PE Ratio (TTM) for today is calculated as:
Athens Medical Centre's share price for today is €1.45.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Athens Medical Centre's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.054.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Athens Medical Centre EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Athens Medical Centre's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Athens Medical Centre's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Athens Medical Centre EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Athens Medical Centre's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Athens Medical Centre's EV-to-EBITDA falls into.
Athens Medical Centre's current Enterprise Value is €294.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Athens Medical Centre's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €27.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Athens Medical Centre (FRA:ACS) has a EV-to-EBITDA of 10.58 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Athens Medical Centre. This is 11% above median its historical median of 9.55. Over the past decade, Athens Medical Centre's EV-to-EBITDA has ranged from 6.15 to 211.64. According to the industry distribution chart, Athens Medical Centre ranks #241 out of 509 companies in the Healthcare Providers & Services industry, placing it in the top 47.3%.
Is Athens Medical Centre's EV-to-EBITDA too high?
Athens Medical Centre's current EV-to-EBITDA of 10.58 is 11% above median its 10-year median of 9.55. Over the past 10 years, this metric has ranged from a low of 6.15 to a high of 211.64. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.07. Athens Medical Centre's value of 10.58 is 4.4% below this industry median. Based on the distribution chart, Athens Medical Centre ranks #241 out of 509 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Athens Medical Centre has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Athens Medical Centre's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Athens Medical Centre ranks #241 out of 509 companies for EV-to-EBITDA. This puts Athens Medical Centre in the upper half of its industry. The industry median EV-to-EBITDA is 11.07. Athens Medical Centre's value of 10.58 is 4.4% below this benchmark. Historically, Athens Medical Centre's own EV-to-EBITDA has ranged from 6.15 to 211.64 over the past decade. While the company's 10-year median is 9.55 vs. the industry median of 11.07, Athens Medical Centre has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.07, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Athens Medical Centre's current EV-to-EBITDA of 10.58 is 4.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Athens Medical Centre. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Athens Medical Centre's current EV-to-EBITDA is 10.58, which is 11% above median its own 10-year median of 9.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Athens Medical Centre stock overvalued right now?
Athens Medical Centre (FRA:ACS) has a current EV-to-EBITDA of 10.58. The stock's GF Value™ is €1.78, compared to a current price of €1.45 — trading 18.5% below its estimated fair value. The current EV-to-EBITDA is 10.58, which is 11% above median its 10-year median of 9.55 and 4.4% below the Healthcare Providers & Services industry median of 11.07. Athens Medical Centre's overall GF Score™ is 63/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Athens Medical Centre (FRA:ACS), the current EV-to-EBITDA is 10.58 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Athens Medical Centre (FRA:ACS) Overvalued in 2026?
Based on GuruFocus' analysis, Athens Medical Centre stock appears to be undervalued.
The current stock price of €1.45 is trading 18.5% below its estimated GF Value™ of €1.78.
Key valuation signals for FRA:ACS:
EV-to-EBITDA: 10.58 (11% above median its 10-year median of 9.55)
GF Value™: €1.78 vs. price of €1.45 (18.5% below fair value)
Industry Position: 4.4% below the Healthcare Providers & Services median (#241 of 509)
No single metric tells the full story. See the FRA:ACS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Athens Medical Centre SA engages in the provision of healthcare services. It includes medical research and methods of treatment, training, and selection of executives and staff on behalf of the hospitals and importation of medical tools, instruments, machinery, and automated devices for the hospitals. Its offering includes medical services in such specializations as pathology, cardiology, general surgery, plastic and vascular surgery, orthopedic, physiotherapy, ophthalmology, urology, neurosurgery, thoracic, pediatric, dermatology, endocrinology and stomatology. The company operates in Domestic healthcare service, Healthcare service provided abroad (Romania) and Sale of medical tools & sanitary/health equipment segment.
63GF Score
Get the complete analysis for FRA:ACS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ACS has been successfully added to your 
